The 'elbow bump' has become popular during the coronavirus pandemic

Image source: Unsplash/Noah

COVID-19 prevention

Social distancing: does it work?

The number of cases tested positive for COVID-19 initially grew exponentially in China, but then slowed down. Dirk Brockmann, professor at Humboldt-Universität zu Berlin (HU) and project group leader at the Robert Koch-Institut (RKI), and his postdoc Benjamin F. Maier have developed a diffusion model that takes into account the effect of social distancing and other measures to explain this effect.

The results of their study have now been published in the online edition of the journal Science. "An exponential growth in case numbers can generally be expected when an infectious disease spreads unhindered," explains Brockmann. "For example, one infected person infects three people, these three people in turn infect three people each - and after a very short time, there are many people who have become ill." According to Brockmann, however, this growth could not be observed in China later. "Since the end of January, the number of cases grew steadily slower and then flattened out."

Recommended article

The theoretical physicists see the cause of this effect as individual behavioral changes in accordance with social distancing or government measures such as contact tracing and curfews. Over time, these lead to fewer and fewer contacts between infected and non-infected persons, which leads to a temporal decrease in the so-called reproduction rate. "If a person infects three more people on average, but then only two people each and then only one person each, the outbreak grows more slowly than exponentially - we call this sub-exponential," explains Brockmann's colleague Maier.

In their model, the researchers assume that, over time, more and more non-infected people are shielded from the spreading process. "Thus, the number of new infections per day soon reaches a maximum and then drops again," says Brockmann. In the meantime, similar effects can be observed in other countries, for example in Italy, Spain or Germany.

A potential tipping point

The researchers are not yet giving the all-clear: "While we are seeing a slight decrease in new infections in Italy and Spain, this behaviour is not yet beginning to show in Germany. So we are currently at a critical point: if the number of contacts continues to fall, the outbreak can be contained. However, if this does not happen, the total number of cases would continue to rise. "A lot now really depends on our own behaviour," says Maier.


Source: Humboldt-Universität zu Berlin

09.04.2020

Read all latest stories

Related articles

Photo

The math behind corona

Predicting the future of the Covid-19 pandemic with data

Mathematical models can help shed light on the evolution of the coronavirus pandemic, according to Spanish mathematician Juan Luis Fernández Martínez, who predicted Spain could have between 90,000…

Photo

Risk assessment

Understanding the spread of COVID-19 on public transport

Researchers at Newcastle University are involved in a study to understand the risks of COVID-19 transmission on public transport and to identify the best measures to control it. Known as Project…

Photo

Flaws in study design

Will COVID-19 vaccines save lives? Right now, we cannot tell

Vaccines are being hailed as the solution to the COVID-19 pandemic, but the vaccine trials currently underway are not designed to tell us if they will save lives, reports Peter Doshi, Associate…

Related products

Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Infectious Disease/Hepatitis

Siemens Healthineers – Versant HCV Genotype 2.0 Assay (LiPA)

Siemens Healthineers